Cite

HARVARD Citation

    Kiyota, N. et al. (n.d.). 2864 Defining 131I-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by 131I-refractory criteria in the SELECT trial. European journal of cancer. pp. S578-. [Online]. 
  
Back to record